Skip to content

Nasdaq · CIK 0001817713

JANX Janux Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing Jun 13, 2025. Close $18.39 on Oct 9, 2026, +51% from the 52-week low and -47% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
19
with a Form 4 at this company

Price and insider trades, last year

JANXOct 9, 2026 · close 18.39

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Janux Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
0WeakAndrew Hollman Meyer
Chief Business Officer
sell
$107k
3,333 shares
-4%+35% from low-52% from high
0WeakAndrew Hollman Meyer
Chief Business Officer
sell
$100k
3,334 shares
-4%+23% from low-56% from high
43ModerateRa Capital Management, L.p.
director, owner
buy
$25M
824,041 shares
+9%-
0WeakAndrew Hollman Meyer
Chief Business Officer
sell
$107k
3,334 shares
-4%-
0WeakAndrew Hollman Meyer
Chief Business Officer
sell
$141k
3,334 shares
-4%-
27WeakDavid Alan Campbell
President and CEO
sell
$300k
5,000 shares
-2%-
29WeakAndrew Hollman Meyer
Chief Business Officer
sell
$732k
13,334 shares
-14%-
43ModerateDavid Alan Campbell
President and CEO
sell
$1.4M
25,000 shares
-10%-
30WeakDavid Alan Campbell
President and CEO
sell
$1.0M
15,000 shares
-6%-
30WeakDavid Alan Campbell
President and CEO
sell
$1.3M
25,000 shares
-9%-
38WeakDavid Alan Campbell
President and CEO
sell
$1.3M
25,000 shares
-8%-
19WeakJay Lichter
owner
sell
$178k
3,815 shares
-35%-
43ModerateRa Capital Management, L.p.
director, owner
buy
$54M
1,200,000 shares
+15%-
50ModerateAvalon Ventures XI, L.P.
owner
sell
$77M
1,673,128 shares
-59%-

Transactions

The last 100 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Jun 11, 2025Sheila Gujrathi
director
AGrant or award
Common Stock
+3,750$0.00$0118,889Jun 13, 2025
Jun 11, 2025Ronald W Barrett
director
AGrant or award
Common Stock
+3,750$0.00$06,250Jun 13, 2025
Jun 11, 2025Natasha Hernday
director
AGrant or award
Common Stock
+3,750$0.00$08,731Jun 13, 2025
Jun 11, 2025Vickie L Capps
director
AGrant or award
Common Stock
+3,750$0.00$074,098Jun 13, 2025
Jun 11, 2025Ra Capital Management, L.p.
director, owner
AGrant or award
Common Stockindirect: See footnotes
+3,750$0.00$06,250Jun 13, 2025
Jun 11, 2025Jake Simson
director
AGrant or award
Common Stock
+3,750$0.00$06,250Jun 13, 2025
Jun 11, 2025Alana B. McNulty
director
AGrant or award
Common Stock
+3,750$0.00$06,250Jun 13, 2025
Jun 11, 2025Winston Kung
director
AGrant or award
Common Stock
+3,750$0.00$06,250Jun 13, 2025
Jun 11, 2025Eric Dobmeier
director
AGrant or award
Common Stock
+3,750$0.00$09,981Jun 13, 2025
Jun 11, 2025Alana B. McNulty
director
AGrant or award
Stock Option (right to buy)derivative
+11,667$0.00$011,667Jun 13, 2025
Jun 11, 2025Natasha Hernday
director
AGrant or award
Stock Option (right to buy)derivative
+11,667$0.00$011,667Jun 13, 2025
Jun 11, 2025Vickie L Capps
director
AGrant or award
Stock Option (right to buy)derivative
+11,667$0.00$011,667Jun 13, 2025
Jun 11, 2025Sheila Gujrathi
director
AGrant or award
Stock Option (right to buy)derivative
+11,667$0.00$011,667Jun 13, 2025
Jun 11, 2025Winston Kung
director
AGrant or award
Stock Option (right to buy)derivative
+11,667$0.00$011,667Jun 13, 2025
Jun 11, 2025Eric Dobmeier
director
AGrant or award
Stock Option (right to buy)derivative
+11,667$0.00$011,667Jun 13, 2025
Jun 11, 2025Jake Simson
director
AGrant or award
Stock Option (right to buy)derivative
+11,667$0.00$011,667Jun 13, 2025
Jun 11, 2025Ronald W Barrett
director
AGrant or award
Stock Option (right to buy)derivative
+11,667$0.00$011,667Jun 13, 2025
Jun 11, 2025Ra Capital Management, L.p.
director, owner
AGrant or award
Stock Option (Right to Buy)derivativeindirect: See Footnotes
+11,667$0.00$011,667Jun 13, 2025
Jun 2, 2025Janeen Noel Doyle
Chief Corp. & Bus. Dev. Ofcr
AGrant or award
Common Stock
+44,000$0.00$044,000Jun 4, 2025
Jun 2, 2025Janeen Noel Doyle
Chief Corp. & Bus. Dev. Ofcr
AGrant or award
Stock option (right to buy)derivative
+154,000$0.00$0154,000Jun 4, 2025
May 1, 2025Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Common Stock10b5-1
+3,333$4.21$14k85,472May 2, 2025
May 1, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-2,933$31.95$94k82,539May 2, 2025
May 1, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-400$32.60$13k82,139May 2, 2025
May 1, 2025Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Stock Option (right to buy)derivative10b5-1
-3,333$0.00$087,332May 2, 2025
Apr 21, 2025Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Common Stock10b5-1
+3,334$4.21$14k85,473Apr 23, 2025
Apr 21, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-3,334$30.00$100k82,139Apr 23, 2025
Apr 21, 2025Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Stock Option (right to buy)derivative10b5-1
-3,334$0.00$090,665Apr 23, 2025
Mar 5, 2025Ra Capital Management, L.p.
director, owner
POpen-market purchase
Common Stockindirect: See footnotes
+304,287$30.56$9.3M9,621,533Mar 7, 2025
Mar 5, 2025Ra Capital Management, L.p.
director, owner
POpen-market purchase
Common Stockindirect: See footnotes
+37,455$31.30$1.2M9,658,988Mar 7, 2025
Mar 6, 2025Ra Capital Management, L.p.
director, owner
POpen-market purchase
Common Stockindirect: See footnotes
+372,093$30.78$11M10,031,081Mar 7, 2025
Mar 7, 2025Ra Capital Management, L.p.
director, owner
POpen-market purchase
Common Stockindirect: See footnotes
+110,206$31.02$3.4M10,141,287Mar 7, 2025
Mar 3, 2025Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Common Stock10b5-1
+3,334$4.21$14k85,473Mar 5, 2025
Mar 3, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-2,433$31.88$78k83,040Mar 5, 2025
Mar 3, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-901$32.85$30k82,139Mar 5, 2025
Mar 3, 2025Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Stock Option (right to buy)derivative10b5-1
-3,334$0.00$093,999Mar 5, 2025
Feb 3, 2025Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Common Stock10b5-1
+3,334$4.21$14k85,473Feb 5, 2025
Feb 3, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-2,418$42.08$102k83,055Feb 5, 2025
Feb 3, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-816$42.77$35k82,239Feb 5, 2025
Feb 3, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-100$43.60$4,36082,139Feb 5, 2025
Feb 3, 2025Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Stock Option (right to buy)derivative10b5-1
-3,334$0.00$097,333Feb 5, 2025
Jan 7, 2025David Alan Campbell
President and CEO
SOpen-market sale
Common Stock10b5-1
-5,000$60.00$300k293,054Jan 8, 2025
Jan 2, 2025Andrew Hollman Meyer
Chief Business Officer
AGrant or award
Common Stock
+18,000$0.00$095,473Jan 3, 2025
Jan 2, 2025David Alan Campbell
President and CEO
AGrant or award
Common Stock
+81,000$0.00$0298,054Jan 3, 2025
Jan 2, 2025Thomas DiRaimondo
Chief Scientific Officer
AGrant or award
Common Stock
+24,000$0.00$0129,719Jan 3, 2025
Jan 2, 2025Maria Dobek
Vice President, Accounting
AGrant or award
Common Stock
+14,000$0.00$014,001Jan 3, 2025
Jan 2, 2025Byron Robinson
Chief Strategy Officer
AGrant or award
Common Stock
+28,000$0.00$028,000Jan 3, 2025
Jan 2, 2025Charles M. Winter
Chief Technical Officer
AGrant or award
Common Stock
+23,000$0.00$077,288Jan 3, 2025
Jan 2, 2025Zachariah McIver
Chief Medical Officer
AGrant or award
Common Stock
+26,000$0.00$026,000Jan 3, 2025
Jan 2, 2025Thomas DiRaimondo
Chief Scientific Officer
AGrant or award
Stock option (right to buy)derivative
+84,000$0.00$084,000Jan 3, 2025
Jan 2, 2025David Alan Campbell
President and CEO
AGrant or award
Stock option (right to buy)derivative
+283,500$0.00$0283,500Jan 3, 2025
Jan 2, 2025Maria Dobek
Vice President, Accounting
AGrant or award
Stock option (right to buy)derivative
+31,500$0.00$031,500Jan 3, 2025
Jan 2, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-2,922$53.76$157k92,551Jan 3, 2025
Jan 2, 2025Byron Robinson
Chief Strategy Officer
AGrant or award
Stock option (right to buy)derivative
+98,000$0.00$098,000Jan 3, 2025
Jan 2, 2025Charles M. Winter
Chief Technical Officer
AGrant or award
Stock option (right to buy)derivative
+80,500$0.00$080,500Jan 3, 2025
Jan 2, 2025Zachariah McIver
Chief Medical Officer
AGrant or award
Stock option (right to buy)derivative
+91,000$0.00$091,000Jan 3, 2025
Jan 2, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-5,768$54.51$314k86,783Jan 3, 2025
Jan 2, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-3,444$55.76$192k83,339Jan 3, 2025
Jan 2, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-1,000$56.78$57k82,339Jan 3, 2025
Jan 2, 2025Andrew Hollman Meyer
Chief Business Officer
SOpen-market sale
Common Stock10b5-1
-200$57.37$11k82,139Jan 3, 2025
Jan 2, 2025Andrew Hollman Meyer
Chief Business Officer
AGrant or award
Stock option (right to buy)derivative
+63,000$0.00$063,000Jan 3, 2025
Dec 24, 2024David Alan Campbell
President and CEO
SOpen-market sale
Common Stock10b5-1
-25,000$56.19$1.4M217,054Dec 27, 2024
Dec 19, 2024Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Common Stock
+9,880$20.24$200k77,472Dec 20, 2024
Dec 19, 2024Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Common Stock
+1$14.02$1477,473Dec 20, 2024
Dec 19, 2024Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Stock Option (right to buy)derivative
-9,880$0.00$096,870Dec 20, 2024
Dec 19, 2024Andrew Hollman Meyer
Chief Business Officer
MOption exercise
Stock Option (right to buy)derivative
-1$0.00$089,999Dec 20, 2024
Dec 3, 2024David Alan Campbell
President and CEO
SOpen-market sale
Common Stock10b5-1
-15,000$67.00$1.0M242,054Dec 3, 2024
Nov 25, 2024David Alan Campbell
President and CEO
SOpen-market sale
Common Stock10b5-1
-18,281$51.43$940k263,773Nov 27, 2024
Nov 25, 2024David Alan Campbell
President and CEO
SOpen-market sale
Common Stock10b5-1
-6,719$52.04$350k257,054Nov 27, 2024
Nov 5, 2024Vickie L Capps
director
JOther
Common Stock
+2,305$0.00$070,348Nov 7, 2024
Nov 5, 2024Sheila Gujrathi
director
JOther
Common Stock
+4,611$0.00$0115,139Nov 7, 2024
Oct 28, 2024David Alan Campbell
President and CEO
SOpen-market sale
Common Stock10b5-1
-13,897$53.22$740k293,157Oct 30, 2024
Oct 28, 2024David Alan Campbell
President and CEO
SOpen-market sale
Common Stock10b5-1
-11,103$53.94$599k282,054Oct 30, 2024
Sep 13, 2024Jay Lichter
owner
MOption exercise
Common Stock
+1,868$17.00$32k8,868Oct 24, 2024
Sep 13, 2024Jay Lichter
owner
MOption exercise
Common Stock
+778$10.73$8,3489,646Oct 24, 2024
Sep 13, 2024Jay Lichter
owner
MOption exercise
Common Stock
+778$13.22$10k10,424Oct 24, 2024
Sep 13, 2024Jay Lichter
owner
MOption exercise
Common Stock
+391$39.80$16k10,815Oct 24, 2024
Sep 13, 2024Jay Lichter
owner
SOpen-market sale
Common Stock
-3,815$46.68$178k7,000Oct 24, 2024
Sep 13, 2024Jay Lichter
owner
MOption exercise
Stock Option (right to buy)derivative
-1,868$0.00$027,138Oct 24, 2024
Sep 13, 2024Jay Lichter
owner
MOption exercise
Stock Option (right to buy)derivative
-778$0.00$011,308Oct 24, 2024
Sep 13, 2024Jay Lichter
owner
MOption exercise
Stock Option (right to buy)derivative
-778$0.00$011,308Oct 24, 2024
Sep 13, 2024Jay Lichter
owner
MOption exercise
Stock Option (right to buy)derivative
-391$0.00$07,682Oct 24, 2024
Oct 18, 2024Ra Capital Management, L.p.
director, owner
POpen-market purchase
Common Stockindirect: See footnotes
+1,200,000$44.75$54M9,317,246Oct 22, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
SOpen-market sale
Common Stock
-60,179$49.69$3.0M2,761,291Oct 18, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
SOpen-market sale
Common Stockindirect: By Avalon BioVentures I, LP
-11,657$49.69$579k534,883Oct 18, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
SOpen-market sale
Common Stockindirect: By Avalon BioVentures SPV I, L.P.
-61,445$49.69$3.1M2,819,366Oct 18, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
SOpen-market sale
Common Stock
-29,474$50.61$1.5M2,731,817Oct 18, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
SOpen-market sale
Common Stockindirect: By Avalon BioVentures I, LP
-5,710$50.61$289k529,173Oct 18, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
SOpen-market sale
Common Stockindirect: By Avalon BioVentures SPV I, LP
-30,094$50.61$1.5M2,789,272Oct 18, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
MOption exercise
Common Stock
+4,968$17.00$84k11,855Oct 18, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
MOption exercise
Common Stock
+2,070$10.73$22k13,925Oct 18, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
MOption exercise
Common Stock
+2,070$13.22$27k15,995Oct 18, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
MOption exercise
Common Stock
+1,407$39.80$56k17,402Oct 18, 2024
Oct 16, 2024Avalon Ventures XI, L.P.
owner
SOpen-market sale
Common Stock
-10,957$50.80$557k6,445Oct 18, 2024
Oct 17, 2024Avalon Ventures XI, L.P.
owner
MOption exercise
Common Stock
+836$17.00$14k7,281Oct 18, 2024
Oct 17, 2024Avalon Ventures XI, L.P.
owner
MOption exercise
Common Stock
+348$10.73$3,7347,629Oct 18, 2024
Oct 17, 2024Avalon Ventures XI, L.P.
owner
MOption exercise
Common Stock
+348$13.22$4,6017,977Oct 18, 2024
Oct 17, 2024Avalon Ventures XI, L.P.
owner
MOption exercise
Common Stock
+237$39.80$9,4338,214Oct 18, 2024
Oct 17, 2024Avalon Ventures XI, L.P.
owner
SOpen-market sale
Common Stock
-1,843$50.02$92k6,371Oct 18, 2024
Oct 18, 2024Avalon Ventures XI, L.P.
owner
SOpen-market sale
Common Stock
-102,732$50.30$5.2M2,629,085Oct 18, 2024
Oct 18, 2024Avalon Ventures XI, L.P.
owner
SOpen-market sale
Common Stockindirect: By Avalon BioVentures I, LP
-19,900$50.30$1.0M509,273Oct 18, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

JANX insider trading: Janux Therapeutics, Inc. | InsiderTell